Drugs / p53: 264-272 peptide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01386502 | Jun → Oct 2011 | breast cancer, colorectal cancer, malignant pancreatic neoplasm, ovarian cancer +1 | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | p53: 264-272 peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01386502 ↗ |
| Action | Deplete | “Researchers have been working on a vaccine that will help the immune system recognize and destroy cells that have the p53 mutation and may be cancerous.” NCT01386502 ↗ |
| Modality | Peptide | “wt p53 (264-272) peptide” NCT01386502 ↗ |
| Route | Subcutaneous | “The vaccine will be administered subcutaneously every 3 weeks” NCT01386502 ↗ |